Search
Close this search box.

Amgen sees rare diseases as ‘fourth pillar’ of growth, driven by pair of 2022 deals

ARTICLE | Product Development

The big biotech spotlights pipeline, outlines commercial steps critical for drugs from Horizon, ChemoCentryx takeouts to reach more patients

By Paul Bonanos, Director of Biopharma Intelligence

February 23, 2024 11:14 PM UTC

Amgen believes the marketed drugs and pipeline it received via the 2022 takeouts of Horizon and ChemoCentryx now position rare diseases as a “fourth pillar” driving the company’s growth, alongside general medicine, oncology and inflammation.

On an investor call late Thursday, management at Amgen Inc. (NASDAQ:AMGN) outlined expectations for four marketed medicines the company thinks will anchor its rare disease business, and described steps it can take to reach larger patient populations for each…